Wang J, et al. - Using Surveillance, Epidemiology, and End Results (SEER) datasets, researchers sought to assess the accurate age-adjusted incidence of prostate small cell carcinoma (SCC), update the clinical and pathological characteristics, as well as survival data of prostate SCC. Selection of a total of 260 patients with prostate SCC was done from the SEER database of the National Cancer Institute between 2004 and 2015. Observations revealed an increase in the incidence of prostate SCC over time. Prostate SCC patients had the average age of 70.25 years. Poor differentiation or no differentiation was observed in more than 90% of tumors. Stage IV was identified in the majority of prostate SCC (77.7%). Lymph node metastases were observed in 49% of patients and distant metastases were observed in 68% of patients (compared with 60.5% of patients with distant metastases between 1973-2003). Interestingly, a high level of PSA (> 10 ng/mL) was evident in only 23.5% patients. Treatment comprised chemotherapy in 58.8% of patients, surgery in 25.4% of patients, and radiotherapy in 31.9% of patients. Survival rates at 1-year, 2-year, and 5-year were 42.1%, 22.1%, and 12.5%, respectively (compared with 47.9%, 27.5%, and 14.3%, respectively, between 1973 and 2003). Patients with regional (distant) metastases had prolongation of OS with chemotherapy from 3 months (2 months) to 12 months (9 months). In multivariate Cox regression analysis, age, race, and stage were identified as independent prognostic factors for prostate SCC patients.